Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 43/2026

24 August 2026

Reykjavik, Iceland/Copenhagen, Denmark, 24 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026.

During the period 17 August to 21 August 2026 Embla Medical has acquired 56,000 shares under the Program at the average price of DKK 29.71. Following the transactions below, the Company holds 2,510,601 shares, corresponding to 0.59% of the Company’s total share capital.

The purpose of the Program is to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Capital Allocation Policy. The Program will end no later than 31 December 2026, but the Company is entitled to discontinue the Program at any time.  

The Company may purchase up to 2,000,000 shares under the Program, corresponding to 0.47% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million.

The Program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (“MAR”), and the Commission’s delegated regulation 2016/1052.

Further information

Klaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134

Embla Medical press releases by e-mail

If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors

About Embla Medical

Embla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations^®. Embla Medical is home to several leading brands renowned for positively impacting people’s health and well-being. They include Össur, a leading global provider of prosthetics and bracing solutions; Fior & Gentz, an innovative developer of neuro orthotics; College Park, a provider of lower limb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic (O&P) patient care facilities. Embla Medical is committed to sustainable business practices, is a signatory to the UN Global Compact and UN Women’s Empowerment Principles and contributes to the UN Sustainable Development Goals. The company’s climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has around 4,500 employees. www.emblamedical.com